Literature DB >> 23306419

Revision total hip arthroplasty in younger patients: indications, reasons for failure, and survivorship.

Joseph A Karam1, Anthony T Tokarski, Michael Ciccotti, Matthew S Austin, Gregory K Deirmengian.   

Abstract

Increasing numbers of total hip arthroplasty (THA) procedures are being performed on younger patients, and the incidence of revision THA in this population is also increasing. The goals of our retrospective study were to survey the surgical indications and reasons for failure and survivorship of revision THA in patients aged < 50 years. We identified 139 cases of revision THA performed over a 6-year period in patients aged < 50 years. The most common reason for revision was aseptic loosening, followed by acetabular liner wear with or without osteolysis. We found an overall 10-year survivorship of 76%. When survivorship was stratified by the indication for revision surgery, revision for wear demonstrated the best 10-year survivorship, while revision for instability or infection exhibited poor survivorship.

Entities:  

Mesh:

Year:  2012        PMID: 23306419     DOI: 10.3810/psm.2012.11.1992

Source DB:  PubMed          Journal:  Phys Sportsmed        ISSN: 0091-3847            Impact factor:   2.241


  3 in total

1.  Revision total hip arthroplasty in the United States: national trends and in-hospital outcomes.

Authors:  Brian E Schwartz; Hristo I Piponov; Cory W Helder; William F Mayers; Mark H Gonzalez
Journal:  Int Orthop       Date:  2016-02-01       Impact factor: 3.075

2.  Early failure for wear after ceramic-on-highly cross-linked polyethylene total hip arthroplasty: a case report.

Authors:  Chenkai Li; Haining Zhang
Journal:  BMC Musculoskelet Disord       Date:  2020-10-10       Impact factor: 2.362

3.  Revision Total Hip Arthroplasty after Ceramic Bearing Fractures in Patients Under 60-years Old; Mid-term Results.

Authors:  Chulsoon Im; Kyung-Jae Lee; Byung-Woo Min; Ki-Cheor Bae; Si-Wook Lee; Hyuk-Joon Sohn
Journal:  Hip Pelvis       Date:  2018-09-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.